Insight Genetics   
分子诊断解决方案，使个性化癌症治疗，改善患者的预后。


Insight Genetics provides molecular diagnostic solutions that enable personalized cancer care and improve patient outcomes. We have a portfolio of assays that detect specific cancer biomarkers and an innovative platform technology for assay development. Our products and services have application in translational research, clinical diagnostics and drug discovery.

Insight has ongoing collaborations with leading academic researchers, physicians and clinicians. With the guidance of these thought leaders, we have developed more accurate and efficient tools for detecting oncogenes indicative of initial therapy response and mutations that confer resistance and might suggest alternative or second-generation treatment options. Insight ALK Screen and Insight ALK Resistance (patents pending) address that cycle for the anaplastic lymphoma kinase (ALK) oncogene, which has an established pathogenic role in more than 1.2 million new cancer diagnoses each year on a worldwide basis.

Insight’s patented platform technology, TEER™, is a highly sensitive and cost-effective method for developing assays that detect single nucleotide polymorphisms (SNPs). The TEER method has applications across numerous industries and end-markets.